We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hologic Acquires Biolucent

By HospiMedica staff writers
Posted on 01 Oct 2007
Hologic, Inc. More...
(Bedford, MA, USA), a leading provider of diagnostic imaging and state-of-the-art digital imaging systems directed towards women's health, has completed the acquisition of BioLucent, Inc. (Aliso Viejo, CA, USA), the developer and marketer of the MammoPad breast cushion.

"This acquisition reflects our continued strategy and efforts to offer a comprehensive portfolio of products to serve in the breast cancer detection market, ” said Jack Cumming, chairman and chief executive officer. "The BioLucent MammoPad was designed to benefit women undergoing mammograms by providing more comfort, we believe, better tissue acquisition, and ultimately improved outcomes. It is our hope, with proper training and support the MammoPad can become a standard of care in mammography. We look forward to the opportunities that will develop from this combination as we continue to build value for our shareholders.”

BioLucent's MammoPad decreases the discomfort associated with mammography. BioLucent's primary research and development efforts are directed at its brachytherapy business, which is focused on breast cancer therapy. Prior to the acquisition, BioLucent completed the spin-off of its brachytherapy technology and business to the holders of BioLucent's outstanding shares of capital stock. The new company, Cianna Medical, will manufacture and market the SAVI applicator. As a result, Hologic acquired BioLucent's Mammopad business and related assets.

The aggregate purchase price paid by Hologic to the security holders of BioLucent at the closing of the acquisition, exclusive of certain transaction costs and expenses, was approximately US$70 million, of which amount $65 million was paid by Hologic in shares of Hologic's common stock.

"We are pleased we have finalized this agreement with Hologic,” said Steven Gex, president and CEO of Biolucent, Inc. "We believe Hologic's experience and ability to work with partners to drive the adoption of value-added products in the sales channel will serve as the perfect compliment to our MammoPad breast cushion.”

Hologic is a leading developer, manufacturer, and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography, and breast biopsy, direct-to-digital X-ray for general radiography applications, and mini C-arm imaging for orthopedic applications.


Related Links:
Hologic
Biolucent

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image Credit: Adobe Stock

Emergency Department Campaign Reduces CT Use Without Identified Missed Injuries

Unnecessary head and cervical spine computed tomography (CT) in low-risk trauma patients exposes them to avoidable radiation, prolongs emergency department stays, and increases healthcare costs.... Read more

Surgical Techniques

view channel
Image: Researchers developed a handheld photothermal mid-infrared spectroscopic imaging (MIRSI) system that measures just 8 square inches. Probe light from a visible (red) diode laser and pump light from a modulated quantum cascade laser (QCL) are coupled into optical fibers and delivered to a flexible, handheld imager (blue dashed box). The beams are combined at a short-pass dichroic mirror and focused onto the sample using an off-axis parabolic mirror (OAP). (Image Credit:Rohith Reddy, University of Houston)

Handheld Infrared Imaging Device Supports Tumor Margin Assessment During Surgery

Accurately determining tumor margins during surgery remains challenging. Frozen-section pathology takes time and can miss residual disease, potentially leading to repeat surgery and delayed therapy.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.